Literature DB >> 31422761

Structure-based virtual screening, molecular dynamics simulation and MM-PBSA toward identifying the inhibitors for two-component regulatory system protein NarL of Mycobacterium Tuberculosis.

Niranjan Kumar1, Rakesh Srivastava1, Amresh Prakash2, Andrew M Lynn1.   

Abstract

The nitrate/nitrite response regulatory protein NarL belongs to the two-component regulatory system of Mycobacterium tuberculosis (MTB), plays a crucial role in anaerobic survival of mycobacteria in host. The absence of this protein in humans, makes it an attractive drug target for MTB treatment. However, the specific drug molecules targeting NarL are yet to be identified. In this study, we identified the promising drug candidates using structure based virtual screening of compounds from chemical libraries (ChEMBL and ZINC), followed by the extensive physicochemical properties analyses and molecular dynamics (MD) simulation. As the initial results, we obtained 4,754 bioactive compounds from ChEMBL having anti-tuberculosis activity which is finally narrowed down to the best 10 hits. A similar approach was applied to search for structurally similar compounds from ZINC data, corresponding to the top hits obtained from ChEMBL. Our collective results show that two compounds, ChEMBL509609 (Gscore - 5.054 kcal/mol, Xscore - 6.47 kcal/mol) and ZINC01843143 (Gscore - 5.114 kcal/mol, Xscore - 6.46 kcal/mol) having the best docking score and ADMET profile. The structural stability and dynamics of lead molecules at active site of NarL were examined using MD simulation and the binding free energies were estimated with MM-PBSA. Essential dynamics and MM-PBSA demonstrated that NarL-ChEMBL509609 complex remains the most stable during simulation of 100 ns with the higher binding free energy which may be a suitable candidate for further experimental analysis. AbbreviationsADMEAbsorption, Distribution, Metabolism, And ExcretionBCGBacillus Calmette-GuerinCNSCentral nervous systemDOTSDirectly observed treatment, short courseEDEssential dynamicsHIVHuman immunodeficiency virusHKHistidine kinaseHOAHuman oral absorptionHTVSHigh throughput virtual screeningIRRIIrritationMDMolecular dynamicsMDRMultidrug resistantMTBMycobacterium tuberculosisMUTMutagenicityMWMolecular weightPHOAPercentage of human oral absorptionREPReproductive developmentRgRadius of gyrationRMSDRoot mean square deviationRMSFRoot mean square fluctuationRO5Lipinski's rule of fiveRRResponse regulatorSPStandard precisionSPGStandard precision glideTBTuberculosisTCSTwo-component regulatory systemTDRTotally drug-resistantTUMOTumorigenicityWHOWorld health organizationXDRExtensively drug-resistantXPExtra precisionCommunicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  MM-PBSA; Mycobacterium tuberculosis; NarL; essential dynamics; virtual screening

Mesh:

Substances:

Year:  2019        PMID: 31422761     DOI: 10.1080/07391102.2019.1657499

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  12 in total

1.  In silico elucidation of the interactions of thymoquinone analogues with phosphatase and tensin homolog (PTEN).

Authors:  Leila Hokmabady; Najmeh Fani
Journal:  J Mol Model       Date:  2022-09-17       Impact factor: 2.172

2.  Identifying the Novel Inhibitors Against the Mycolic Acid Biosynthesis Pathway Target "mtFabH" of Mycobacterium tuberculosis.

Authors:  Niranjan Kumar; Rakesh Srivastava; Raj Kumar Mongre; Chandra Bhushan Mishra; Amit Kumar; Rosy Khatoon; Atanu Banerjee; Md Ashraf-Uz-Zaman; Harpreet Singh; Andrew M Lynn; Myeong-Sok Lee; Amresh Prakash
Journal:  Front Microbiol       Date:  2022-05-06       Impact factor: 6.064

Review 3.  Targeting a highly conserved domain in bacterial histidine kinases to generate inhibitors with broad spectrum activity.

Authors:  Conrad A Fihn; Erin E Carlson
Journal:  Curr Opin Microbiol       Date:  2021-04-28       Impact factor: 7.584

4.  Discovering Potential RNA Dependent RNA Polymerase Inhibitors as Prospective Drugs Against COVID-19: An in silico Approach.

Authors:  Satabdi Saha; Rajat Nandi; Poonam Vishwakarma; Amresh Prakash; Diwakar Kumar
Journal:  Front Pharmacol       Date:  2021-02-26       Impact factor: 5.810

5.  Dieckol and Its Derivatives as Potential Inhibitors of SARS-CoV-2 Spike Protein (UK Strain: VUI 202012/01): A Computational Study.

Authors:  Mohammad Aatif; Ghazala Muteeb; Abdulrahman Alsultan; Adil Alshoaibi; Bachir Yahia Khelif
Journal:  Mar Drugs       Date:  2021-04-25       Impact factor: 5.118

6.  Specific Inhibition of VanZ-Mediated Resistance to Lipoglycopeptide Antibiotics.

Authors:  Vishma Pratap Sur; Aninda Mazumdar; Vladimir Vimberg; Tommaso Stefani; Ladislav Androvic; Lucie Kracikova; Richard Laga; Zdenek Kamenik; Katerina Komrskova
Journal:  Int J Mol Sci       Date:  2021-12-22       Impact factor: 5.923

Review 7.  Drug Discovery of Plausible Lead Natural Compounds That Target the Insulin Signaling Pathway: Bioinformatics Approaches.

Authors:  Siba Shanak; Najlaa Bassalat; Ahmad Barghash; Sleman Kadan; Mahmoud Ardah; Hilal Zaid
Journal:  Evid Based Complement Alternat Med       Date:  2022-03-20       Impact factor: 2.629

8.  Targeting SARS-CoV-2 spike protein of COVID-19 with naturally occurring phytochemicals: an in silico study for drug development.

Authors:  Preeti Pandey; Jitendra Subhash Rane; Aroni Chatterjee; Abhijeet Kumar; Rajni Khan; Amresh Prakash; Shashikant Ray
Journal:  J Biomol Struct Dyn       Date:  2020-07-22

9.  Insights into the biased activity of dextromethorphan and haloperidol towards SARS-CoV-2 NSP6: in silico binding mechanistic analysis.

Authors:  Preeti Pandey; Kartikay Prasad; Amresh Prakash; Vijay Kumar
Journal:  J Mol Med (Berl)       Date:  2020-09-23       Impact factor: 4.599

Review 10.  Drug Discovery for Mycobacterium tuberculosis Using Structure-Based Computer-Aided Drug Design Approach.

Authors:  Murtala A Ejalonibu; Segun A Ogundare; Ahmed A Elrashedy; Morufat A Ejalonibu; Monsurat M Lawal; Ndumiso N Mhlongo; Hezekiel M Kumalo
Journal:  Int J Mol Sci       Date:  2021-12-09       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.